Drug Trial Radar · NCT05540288
NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions
Last checked: Nov 20, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
266
Planned (sponsor's estimate)
Start
Mar 31, 2023
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Nantes University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Behavioural addictions (BAs) \[gambling disorder (GD), food addiction (FA), sexual addiction (SA)\] may lead to disastrous consequences. They are often associated with other addictive or psychiatric disorders, and high rates of suicide attempts. Epidemiological studies report prevalence reaching 2.7% for GD, 5% for SA, and up to 7.9% for FA. Many similarities have been highlighted between BAs, as well as with substance use disorders. One core clinical similarity between those disorders is craving (uncontrollable urge to engage in rewarding behaviours), which has been consistently associated with diminished control over the behaviour and relapse. At present, no pharmacological treatment has been approved for BAs, but several medications have been tested. Among them, two opioid receptor antagonists - naltrexone and nalmefene - appear the most promising. By decreasing dopamine neurotransmission in the reward circuitry, they reduce both excitement for rewarding behaviours and craving. Compared to naltrexone, nalmefene seems to have a better safety. To date, no study investigated the efficacy of nalmefene as a pan-addiction treatment for BAs. Two clinical trials have demonstrated its efficacy for the treatment of GD, but no clinical trial was conducted for FA and SA. The investigators hypothesise that nalmefene (36 mg/d), compared to a placebo, can have a therapeutic effect as an add-on to usual treatment for decreasing craving in several BAs.
Conditions
- Behavioural Addiction
Interventions
NalmefeneDrug
Week 1: 18 mg/d Week 2: 1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d 2. In the presence of grade 3 ARs, 18 mg/d 3. In the presence of grade 4 ARs, treatment will be stopped immediately. Week 3 to week 5: 1. In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage 2. In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped. 3. In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage 4. In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d 5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.
PlaceboDrug
Week 1: 1 tablet/d Week 2: 1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d 2. In the presence of grade 3 ARs, 1 tablet/d 3. In the presence of grade 4 ARs, the treatment will be stopped immediately. Week 3 to week 5: 1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage 2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped. 3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage 4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d 5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Variation of averaged intensity of craving episodes between start and end of treatment.Time frame: 5 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
CHU de Besançon
Besançon, France · Not yet recruiting
CHU de Bordeaux
Bordeaux, France · Recruiting
CHRU de Brest
Brest, France · Recruiting
CHU de Clermont Ferrand
Clermont-Ferrand, France · Recruiting
CHU de Dijon
Dijon, France · Not yet recruiting
CH de La Rochelle
La Rochelle, France · Recruiting
Hospices Civils de Lyon
Lyon, France · Recruiting
CHU de Montpellier
Montpellier, France · Not yet recruiting
CHU de Nantes
Nantes, France · Recruiting
CHU de Nîmes
Nîmes, France · Recruiting
Hôpitaux Universitaires de Strasbourg
Strasbourg, France · Recruiting
CHRU de Tours
Tours, France · Recruiting
Hôpital Paul Brousse
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.